For the Inventor, By the Inventor

Enter assignee name

Lehi, UT, United States of America

Tolero Pharmaceuticals, Inc.

USPTO Granted Patents = 21

EPO Patents = 7

Forward Citations = 194

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

David J Bearss (13 out of 50 patents)

Steven L Warner (11 out of 36 patents)

Adam Siddiqui-Jain (8 out of 25 patents)

4. Yong Xu (7 out of 34 patents)

5. Xiaohui Liu (6 out of 11 patents)

6. Michael David Saunders (6 out of 9 patents)

7. Koc-Kan Ho (6 out of 50 patents)

8. Clifford J Whatcott (5 out of 9 patents)

9. Jason Marc Foulks (3 out of 7 patents)

10. Jihua Liu (3 out of 11 patents)

11. Kenneth Mark Parnell (3 out of 11 patents)

12. Benjamin Gary Brenning (3 out of 4 patents)

13. Steven G Kultgen (3 out of 9 patents)

14. Scott Albert Pearce (3 out of 4 patents)

15. Kevin Bret Wright (3 out of 5 patents)

21 patents: Sort by Forward Citations

1. 10682356 - Combination therapies for treatment of cancer (2020-06-16),

2. 10624880 - Predicting response to alvocidib by mitochondrial profiling (2020-04-21),

3. 10568887 - Combination therapies for treatment of cancer (2020-02-25),

4. 10562925 - Alvocidib prodrugs having increased bioavailability (2020-02-18),

5. 10472328 - PKM2 modulators and methods for their use (2019-11-12),

6. 10422788 - Profiling peptides and methods for sensitivity profiling (2019-09-24),

7. 10392392 - Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2019-08-27),

8. 10357488 - Predicting response to alvocidib by mitochondrial profiling (2019-07-23),

9. 10267787 - Profiling peptides and methods for sensitivity profiling (2019-04-23),

10. 10259835 - Alvocidib prodrugs having increased bioavailability (2019-04-16),

11. 10207996 - PKM2 modulators and methods for their use (2019-02-19),

12. 10202356 - JAK2 and ALK2 inhibitors and methods for their use (2019-02-12),

13. 10132797 - Profiling peptides and methods for sensitivity profiling (2018-11-20),

14. 10047093 - Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2018-08-14),

15. 9901574 - Predicting response to alvocidib by mitochondrial profiling (2018-02-27),

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics to treat cancer and hematologic diseases. We strive to improve patient outcomes by targeting dysregulated molecular pathways with novel small molecule inhibitors. With a commitment to scientific excellence and collaboration, we aim to make a lasting and positive impact on patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

21 Patents

#10 in Lehi, UT

#170 in Utah

#15,181 in US

#29,080 in the World

Lehi, UT, United States of America

Tolero Pharmaceuticals, Inc.

Forward Citations = 194

26 inventors:

David J Bearss (13 out of 50 patents)

Steven L Warner (11 out of 36 patents)

Adam Siddiqui-Jain (8 out of 25 patents)

4. Yong Xu (7 out of 34 patents)

5. Xiaohui Liu (6 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…